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Introduction
Food avoidance is still considered the gold-standard
treatment for food allergy (FA). However, recently it has
been consolidating the theory that, where possible, the
food intake might facilitate the induction of desensitiza-
tion and tolerance, resulting more effective and safer -if
we consider the possibility of accidental ingestion- than
a strict avoidance diet [1].
Furthermore, specific oral immunotherapy (OIT) is
the unique active treatment for IgE-mediated FAs [1].
Efficacy
Studies have shown short-term efficacy: namely theOIT-
ability to induce desensitization (loss of responsiveness
to food-antigen during continuous assumption of OIT-
doses) [2-5]. Conversely, data are still insufficient and
controversial regarding long-term efficacy: namely, the
achievementof tolerance(configured when the offending
food is removed from the diet and, if reintroduced, does
not elicit any adversereaction) [2-5].
Recent data have shown that a key role in the induc-
tion of tolerance by OIT is played by a subgroup of reg-
ulatory T cells known as “induced T reg” (iTreg) [6,7].
Epigenetic studies in vivo assessthatOIT determines
hypomethylation of FOXP3 protein in specific antigen-
iTreg only in individuals tolerant. Therefore, changes in
the DNA of iTreg - specific antigen may predict the
development of a state of clinical immune tolerance
during OIT [8].
Safety
About safety, allergic reactions occurred in the majority
of patients treated. They are primarily mild reactions,
severe in about 4%; however, no threatening-life events
nor death has been reported [9]. Frequency and severity
of side effects seem reduced in protocols involving more
gradual dose increases [1].
Careful clinical monitoring by qualified personnel in a
medical environment is essential. Consequently, OIT
costs are high.
In all immunotherapy treatments, safety is of para-
mount importance. Therefore, when severe adverse
reactions occur, OIT should be stopped and revaluated.
Possible approches improving OIT
Several efforts have been made to perfect OIT: e.g.anti-
gens with reduced allergenicity and adjuvants inducing
faster immune responses of “protection”. Particularly
promising is OIT associated with omalizumab, anti-IgE
antibody, resulting safe and able to accelerate the desen-
sitization compared to traditional protocols [10-12].
Conclusions
Further researches are needed in order to verify the
degree of long-term safety as well as the long-term effi-
cacy of OIT.
Given the interest and the celerity of development of
this field of research in the recent years, we are confi-
dent in the near achievement of a personalized treat-
ment, planned, safe and effective, to be used in clinical
practice.
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